|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 185.87 USD | +0.05% |
|
+0.47% | -11.37% |
| Dec. 02 | Icon survey reveals increasing clinical trial startup delays | RE |
| Dec. 02 | Icon plc Announces Results of Its Latest Industry Survey | CI |
Business description: ICON Public Limited Company
Number of employees: 39,800
Sales by Activity: ICON Public Limited Company
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Medical Labs & Research | 2.8B | 5.48B | 7.74B | 8.12B | 8.28B |
Geographical breakdown of sales: ICON Public Limited Company
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States (U.S.) | 926M | 2.58B | 3.57B | 3.28B | 2.99B |
Ireland | 1.18B | 1.37B | 1.98B | 2.38B | 2.79B |
Rest of Europe | 417M | 1.18B | 1.62B | 1.57B | 1.56B |
Rest of world | 274M | 358M | 564M | 884M | 943M |
Executive Committee: ICON Public Limited Company
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 52 | 2024-09-30 | |
Tom O'Leary
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Administrative Officer | 50 | 2016-06-30 | |
Simon Holmes
CIO | Chief Investment Officer | - | - |
Kate Haven
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: ICON Public Limited Company
| Director | Title | Age | Since |
|---|---|---|---|
John Climax
CHM | Chairman | 72 | 2002-10-31 |
Ciaran Murray
CHM | Chairman | 62 | 2017-02-28 |
Stephen Cutler
BRD | Director/Board Member | 64 | 2015-11-24 |
Eugene McCague
BRD | Director/Board Member | 66 | 2017-10-03 |
Rónán Murphy
BRD | Director/Board Member | 67 | 2016-10-17 |
Julie O'Neill
BRD | Director/Board Member | 59 | 2019-07-22 |
Linda Grais
BRD | Director/Board Member | 67 | 2021-06-30 |
| Director/Board Member | 57 | 2024-07-22 |
Company details: ICON Public Limited Company
Group companies: ICON Public Limited Company
| Name | Category and Sector |
|---|---|
ICON Clinical Research India Pvt Ltd.
 ICON Clinical Research India Pvt Ltd. Provides clinical research and development services | |
ICON Clinical Research Ltd.
 ICON Clinical Research Ltd. Provides consulting, outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, government and public health organisations | |
Icon Investments (UK) Ltd. | |
DOCS Resourcing Ltd.
 DOCS Resourcing Ltd. Provides health care services | |
ICON Global Treasury Unlimited Co.
 ICON Global Treasury Unlimited Co. Provides financial services |
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.05% | +0.47% | -11.28% | -9.23% | 14.19B | |
| -0.95% | -1.24% | +4.46% | +9.05% | 47.37B | |
| +0.41% | -1.81% | +12.96% | +6.57% | 38.46B | |
| -2.56% | -5.20% | +60.12% | +71.11% | 35.73B | |
| +0.38% | -1.24% | +10.59% | +19.98% | 27.23B | |
| +0.61% | -7.48% | +60.13% | +166.73% | 15.44B | |
| +1.48% | +2.42% | +68.37% | +227.47% | 15.4B | |
| +0.43% | -1.63% | +44.21% | - | 13.64B | |
| -0.16% | -1.27% | +122.26% | +109.54% | 13.23B | |
| -1.51% | -3.24% | +55.55% | +72.03% | 12.55B | |
| Average | -0.51% | -2.03% | +42.74% | +74.81% | 23.32B | |
| Weighted average by Cap. | -0.61% | -2.15% | +33.81% | +54.94% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ICLR Stock
- Company ICON Public Limited Company
Select your edition
All financial news and data tailored to specific country editions
